金河生物 (002688.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	3.0B	2.9B	2.4B	2.2B	2.1B
Cost of Revenue	2.0B	1.9B	1.6B	1.5B	1.5B
Gross Profit	1.0B	974.5M	794.4M	642.5M	613.8M
Operating Expenses
R&D Expense	113.4M	116.5M	94.0M	74.0M	82.3M
SG&A Expense	—	—	—	—	—
General & Admin Expense	375.0M	361.0M	285.8M	246.4M	239.0M
Selling & Marketing Expense	170.1M	166.8M	138.3M	143.4M	130.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	778.4M	759.6M	602.6M	526.4M	475.4M
Cost and Expenses	2.8B	2.7B	2.2B	2.1B	2.0B
Operating Income (EBIT)	59.7M	42.5M	98.6M	104.7M	121.2M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	56.5M	39.1M	97.8M	101.5M	118.8M
Income Tax Expense	55.9M	50.1M	13.5M	7.1M	730.2K
Bottom Line
Net Income	38.7M	27.6M	100.2M	86.5M	75.6M
Earnings from Cont. Ops	573.3K	(11.0M)	84.3M	94.4M	118.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	38.7M	27.6M	100.2M	86.5M	75.6M
Per Share
Basic EPS	CN¥0.05	CN¥0.04	CN¥0.13	CN¥0.11	CN¥0.10
Diluted EPS	CN¥0.05	CN¥0.04	CN¥0.13	CN¥0.11	CN¥0.10
Revenue Per Share	CN¥3.89	CN¥3.69	CN¥3.06	CN¥2.79	CN¥2.72
Shares
Basic Shares Outstanding	769.1M	780.6M	774.3M	780.3M	780.4M
Diluted Shares Outstanding	769.1M	780.6M	774.3M	780.3M	780.4M
Profitability Metrics
EBITDA	—	278.4M	288.7M	279.3M	272.6M
D&A	—	235.9M	190.2M	174.5M	151.3M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026